# PDAC

Title: The GABAergic Governor: Uncoupling of Tonic Inhibition Drives Pancreatic Cancer
Subtitle: Loss of the metabolic GAD67 constraint unmasks the oncogenic potential of ionotropic GABA-A signaling in PDAC.

Abstract 
Pancreatic Ductal Adenocarcinoma (PDAC) exhibits a paradoxical GABAergic phenotype: the neurotransmitter GABA acts as a tumor suppressor via GABA-B receptors but promotes proliferation via the GABA-A $\pi$-subunit (GABRP). We propose the "Unopposed Excitation Hypothesis" to resolve this. We posit that in healthy tissue, the oncogenic potential of ionotropic GABA-A signaling is strictly governed by the tonic, counter-regulatory force of metabotropic GABA-B receptors. Carcinogenesis begins with the metabolic collapse of GAD67-mediated GABA synthesis, driven by a deficiency in the cofactor pyridoxal 5'-phosphate (PLP). This loss of the "metabolic governor" uncouples the system, leaving the depolarizing GABRP pathway to act as an unconstrained mitogen, driving constitutive calcium entry and MAPK activation. Consequently, the tumor shifts toward reductive carboxylation to manage the resulting glutamatergic toxicity. We argue that restoring the inhibitory clamp via high-affinity GABA-B agonists, rather than general blockade, offers a requisite therapeutic avenue.

In a Nutshell

The Paradox: GABA signaling in PDAC is Janus-faced, suppressing migration via metabotropic pathways while driving stemness via ionotropic pathways.

The Model: We propose a "Governor Model" wherein tonic GABA-B inhibition normally clamps the oncogenic potential of ionotropic excitation.

The Lesion: Metabolic failure of GAD67 removes this constraint, allowing the GABRP "accelerator" to drive proliferation via voltage-gated calcium channels.

The Consequence: The tumor adopts a "Reverse TCA" metabolism as a thermodynamic defense against the resulting glutamatergic voltage.

Main Text

Introduction: The Unclamped Organ
Pancreatic Ductal Adenocarcinoma (PDAC) is frequently characterized as a "neuro-endocrine" malignancy, a definition supported by its extensive perineural invasion and aberrant expression of neural proteins . Among these, the Gamma-Aminobutyric Acid (GABA) system presents a critical paradox. Current literature identifies GABA as a contradictory signal in pancreatic pathology. One body of evidence demonstrates that GABA acts as a potent tumor suppressor, inhibiting cell migration and proliferation via cAMP-dependent pathways . Conversely, independent studies identify the overexpression of the GABA-A receptor $\pi$-subunit (GABRP) as a primary driver of stemness, metastasis, and poor prognosis .

How can the same signaling molecule function as both a brake and an accelerator? We propose that these findings are not contradictory but represent two sides of a broken regulatory architecture. We argue that the transition to malignancy is driven by the uncoupling of the GABAergic circuit. In healthy tissue, ionotropic excitation (GABA-A) is constrained by metabotropic polarity (GABA-B). In PDAC, the metabolic failure of GABA synthesis removes the Governor, leaving the excitation machinery stuck in the "open" position. This hypothesis suggests that PDAC is not merely a genetic disease but a failure of "metabolic gating," where the loss of inhibitory tone unmasks the latent oncogenic potential of the tissue’s own secretory machinery.

The Physiological Governor: Tonic Constraint
To understand the pathology, one must first appreciate the "GABAergic Polarity" of the healthy pancreas. The organ functions as a high-energy secretory machine, necessitating a robust dampening system to prevent secretory signals from becoming proliferative noise. This governor is mediated by the constitutive activity of Glutamate Decarboxylase 67 (GAD67), the rate-limiting enzyme for GABA synthesis .

Unlike its isoform GAD65, which is activated on demand, GAD67 provides a tonic, basal supply of GABA that acts autocrinely and paracrinely on high-affinity GABA-B receptors (GABABR) . These G-protein coupled receptors function as the "Metabolic Clamp." Upon activation, GABA-B inhibits adenylyl cyclase, reducing intracellular cyclic AMP (cAMP) and closing voltage-gated calcium channels . This tonic inhibition specifically counteracts the pro-proliferative $\beta$-adrenergic signaling pathways that are often hyperactive in systemic stress states . As long as GAD67 maintains this inhibitory tone, the cell remains quiescent, even in the presence of excitatory stimuli.

The Primary Lesion: Failure of the Restraint
We posit that the inciting event in PDAC is the functional downregulation of GAD67 activity. This failure is likely metabolic rather than genetic. GAD67 has an absolute requirement for the cofactor Pyridoxal 5'-Phosphate (PLP), the active form of Vitamin B6 .

Systemic inflammation and oxidative stress—hallmarks of the pre-malignant state—rapidly deplete intracellular PLP pools . This creates a "Type 3" metabolic lesion where the enzymatic machinery for inhibition exists but lacks the fuel to function. The result is the evaporation of the Inhibitory Tone. Without the constitutive production of GABA, the GABA-B receptors disengage. The "clamp" is lifted. Crucially, this leaves the cell's $\beta$-adrenergic receptors unopposed, allowing circulating catecholamines to drive unchecked cAMP production and glycolysis . This metabolic uncoupling creates a permissive environment for the secondary, more aggressive pathology: unopposed ionotropic excitation.

The Mechanism of Pathology: Derepressed Voltage
In the absence of the metabolic governor, the expression profile of the acinar cell shifts. The downregulation of the inhibitory arm is accompanied by the upregulation of the GABA-A receptor $\pi$-subunit (GABRP) . In the adult central nervous system, GABA-A activation is inhibitory because it facilitates chloride influx. However, in pancreatic epithelial cells, the chloride gradient is reversed due to the high expression of the NKCC1 transporter . Consequently, GABRP activation drives chloride efflux, leading to membrane depolarization.

In a governed cell, this depolarization is buffered by the hyperpolarizing force of GABA-B. But in an unclamped cell, GABRP activation acts as an "Unopposed Accelerator." The sustained depolarization opens L-type Voltage-Gated Calcium Channels (VGCCs), leading to a chronic influx of intracellular calcium . This calcium surge is the spark that ignites the oncogenic engine: it directly activates the RAS/RAF/MEK/ERK cascade, a well-established driver of PDAC proliferation .

This model resolves the GABRP paradox. The receptor behaves as an oncogene not because it is inherently malignant, but because the counter-regulatory circuit that normally confines its activity has failed. The tumor is not "inventing" new signaling; it is running physiological signaling without a governor.

Metabolic Consequence: The Thermodynamic Defense
The failure of GAD67 leads to a secondary crisis: the accumulation of unconverted Glutamate. In a healthy cell, Glutamate is the substrate for the "Coolant" (GABA). In the GAD67-deficient cell, it becomes a "Fuel" that threatens excitotoxicity. To survive this load, the cancer cell fundamentally reprograms its mitochondria toward Reductive Carboxylation (the Reverse TCA cycle) .

Instead of oxidizing Glutamate in the forward TCA cycle—which would generate NADH and further reactive oxygen species (ROS)—the tumor cell forces the cycle backward: $\alpha$-ketoglutarate is reduced to citrate . This metabolic U-turn serves a critical thermodynamic function. It acts as a "Voltage Sink," converting the toxic excitatory energy of Glutamate into inert lipid biomass . This explains the profound lipogenic phenotype of PDAC: the tumor builds a lipid fortress to contain the derepressed excitation that its failed governor can no longer dampen.

The "Predatory" Phenotype: Perineural Invasion
This governor model also offers a mechanistic explanation for Perineural Invasion (PNI), a hallmark of PDAC. PNI is often described as a path of least resistance, but we argue it is an active "Metabolic Foraging." Nerves are rich sources of GABA, Serine, and Glycine—the very metabolites the tumor cannot synthesize due to GAD67 failure . The GABA-deficient tumor invades the neural plexus to access an exogenous source of inhibition. It is a "starving" tissue attempting to plug itself into the host's neural governor to stabilize its own chaotic membrane potential.

Conclusions and Prospects
The "Unopposed Excitation" hypothesis suggests that PDAC is a disease of signaling uncoupling. Therapies that target the tumor's growth (e.g., cytotoxic chemotherapy) often fail because they increase the systemic oxidative stress that further depletes PLP and weakens the governor .

A more rational approach involves "Metabolic Re-Gating":

Restoring the Clamp: The use of high-affinity GABA-B agonists (e.g., baclofen) can bypass the defective GAD67 enzyme and manually re-engage the inhibitory shield . This has been shown to suppress PDAC progression in animal models by re-imposing cAMP constraints.

Refueling the Governor: Correcting the underlying PLP deficiency through high-dose cofactor supplementation may restore endogenous GAD67 activity, allowing the tissue to resume its own autoregulation .

Dampening the Voltage: The use of NKCC1 inhibitors (e.g., bumetanide) could reverse the chloride gradient, turning the GABRP "accelerator" back into a neutral gear .

By reframing PDAC as a failure of "Metabolic Goodliness"—a failure of the structural capacity to inhibit noise—we open a new therapeutic frontier focused on restoring organ polarity rather than merely poisoning proliferation.



Author Information

IL WOONG CHOI

INDEPENDENT RESEARCHER

iwchoikr@gmail.com



References

Demols A, Le Moine O, Desalle F, Quertinmont E, Van Laethem JL, Devière J. Neuro-endocrine differentiation in pancreatic cancer. J Clin Gastroenterol. 2000;30(4):425-432.

Schuller HM, Al-Wadei HA. The GABAB receptor is a novel drug target for pancreatic cancer. Cancer. 2008;112(4):767-778.

Takehara A, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res. 2007;67(20):9704-9712.

Korpershoek E, Verhofstad AA, Kruijff S, et al. GAD67 mRNA expression in the human fetal and adult pancreas. J Histochem Cytochem. 2007;55(7):665-673.

Al-Wadei HA, Al-Wadei MH, Schuller HM. GABA targets the EGFR pathway to suppress pancreatic cancer. J Oncol. 2012;2012:360206.

Zhang D, Ma Q, Wang X, et al. The role of beta-adrenergic receptors in pancreatic cancer cell proliferation and invasion. Hepatogastroenterology. 2010;57(99-100):638-642.

Schuller HM. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs. 2008;19(7):655-671.

Cellini B, Montioli R, Voltattorni CB. Molecular insights into the binding of PLP to human GAD65 and GAD67. Biochim Biophys Acta. 2012;1824(11):1265-1275.

Merz KE, Cheng TY, Park SY. Vitamin B6, vitamin B12 and methionine and risk of pancreatic cancer: A Scoping Review. Int J Cancer. 2020;146(10):2669-2680.

Toriumi K, Miyashita M, Suzuki K. Vitamin B6 deficiency hyperactivates the noradrenergic signaling system, resulting in social deficits. Transl Psychiatry. 2021;11(1):262.

Li S, Zhu X. Chloride channels and their modulators in cancer. Exp Ther Med. 2018;15(3):2245-2252.

Sung HY, Yang SD, Park SY. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling. Gut. 2012;61(11):1664-1672.

Diep CH, Zollman A, Cappello P. The role of the ERK pathway in pancreatic cancer. J Signal Transduct. 2012;2012:420128.

Mullen AR, Wheaton WW, Jin ES, et al. Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion. Cell Metab. 2012;15(6):813-826.

Fendt SM, Bell EL, Keibler MA, et al. Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio. Nature. 2013;498(7453):214-218.

Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481(7381):380-384.

Amit M, Na'ara S, Gil Z. Axon-cancer connections via neurotransmitters. Nat Rev Cancer. 2016;16(2):106-120.

Galluzzi L, Vacchelli E, Michels J, et al. Vitamin B6 metabolism in cancer. Cell Cycle. 2013;12(24):3760.

Al-Wadei MH, Al-Wadei HA, Schuller HM. Effects of GABAB receptor agonists and antagonists on glycemia and pancreatic cancer. Eur J Pharmacol. 2009;615(1-3):218-222.

Wierzbicki PM, Rybarczyk A. GABAergic signaling as a potential therapeutic target in cancers. J Clin Med. 2020;9(5):1307.

Jiang S, Zhang M, Zhang Y, Zhou W, Zhu T, Ruan S. GABRP is a potential prognostic biomarker and correlated with immune infiltration in pancreatic cancer. J Cancer. 2019;10(26):6599-6610.

Feng ZC, Li J, Li X, et al. GABRP overexpression drives pancreatic ductal adenocarcinoma stemness. Stem Cells Int. 2017;2017:8526181.

Gout J, Pommier RM. GABAergic signaling in the pancreas: From physiology to pathology. World J Gastrointest Pathophysiol. 2013;4(3):62-71.

Prabhu A, Sarcar B. Glutamine metabolism in pancreatic cancer. Cancer Lett. 2014;351(2):197-205.

Kim KP, Mahidhara R. Prognostic value of GABRP in pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9(5):808-815.

Hagan DW, Wright JR Jr, Borden P. The role of GABA in islet function. Front Endocrinol (Lausanne). 2022;13:972115.

Schuller HM. GABA-B receptor agonists for the treatment of pancreatic cancer. Expert Opin Investig Drugs. 2014;23(11):1453-1457.

Zhang J, Pavlova NN, Thompson CB. Cancer cell metabolism: the essential role of the non-essential amino acid, glutamine. EMBO J. 2017;36(10):1302-1315.

Zhu Y, Li Y, Li Z, et al. GABRP promotes the proliferation and metastasis of pancreatic cancer. Oncol Lett. 2020;20(3):2257-2266.

Zhang J, Pavlova NN, Thompson CB. Reductive glutamine metabolism contributes to the survival of cancer cells under metabolic stress. Cancer Lett. 2017;393:7-15.



